Literature DB >> 18045058

Non-receptor tyrosine kinase inhibitors in lung cancer.

Olwen Hahn1, Ravi Salgia.   

Abstract

Lung cancer is a leading cause of cancer death. Systemic therapies with cytotoxic chemotherapies remain ineffective. Current research efforts in lung cancer have focused on developing novel agents to target cellular pathways that are altered in lung cancer. Protein tyrosine kinases are a family of oncogenes that regulate important cellular processes such as differentiation, proliferation, cell cycle, motility, and apoptosis. In this article, we review non receptor tyrosine kinases' role in lung cancer and the development of agents that target these proteins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18045058     DOI: 10.2174/187152007784111322

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  3 in total

1.  Bacterial expression and purification of interleukin-2 tyrosine kinase: single step separation of the chaperonin impurity.

Authors:  Raji E Joseph; Amy H Andreotti
Journal:  Protein Expr Purif       Date:  2008-04-11       Impact factor: 1.650

Review 2.  MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells.

Authors:  Amirhosein Maharati; Amir Sadra Zanguei; Ghazaleh Khalili-Tanha; Meysam Moghbeli
Journal:  Cell Commun Signal       Date:  2022-03-09       Impact factor: 5.712

3.  Houttuynia cordata Thunb extract modulates G0/G1 arrest and Fas/CD95-mediated death receptor apoptotic cell death in human lung cancer A549 cells.

Authors:  Yuh-Fung Chen; Jai-Sing Yang; Wen-Shin Chang; Shih-Chang Tsai; Shu-Fen Peng; Yuan-Ru Zhou
Journal:  J Biomed Sci       Date:  2013-03-19       Impact factor: 8.410

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.